Dupixent, Flu Vaccine Demand Boost Sanofi's Q3 Earnings, Lifts Annual Outlook

  • Sanofi SA SNY said it now expects 2022 adjusted earnings per share to grow by about 16%. The positive currency impact on 2022 business EPS is estimated at +9.5% to +10.5%. It had previously forecast growth of 15%.
  • The company reported Q3 sales of €12.48 billion, +19.7% Y/Y supported by the strong performance of specialty care driven by Dupixent, Flu vaccines, and core assets from General Medicines.
  • Dupixent sales increased 44.5% to €2.3 billion.
  • Related: Sanofi Ends Development Of Breast Cancer Drug Amcenestrant After Trial Failure.
  • It also reported a 26.5% rise in third-quarter business operating income, or adjusted earnings before interest and tax, to €4.5 billion.
  • Sanofi wrote off €1.56 billion, the value of the most advanced drug project of Synthorx that Sanofi agreed to acquire for $2.5 billion in 2019. 
  • Sales from influenza vaccines jumped by a currency-adjusted 32.4% to €1.99 billion, mainly driven by higher influenza vaccine sales.
  • Price Action: SNY shares closed 1.13% higher at $42.05 during after-hours trading on Thursday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsGuidanceHealth CareGeneralBriefsEurasia
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!